Charles Link

Charles Link is an accomplished founder and leader in the biopharmaceutical industry, serving as Founder, President, and Chief Medical Officer of Syncromune since December 2020 and as Founder and Chairman of ChainLink Pharma since January 2021. Under Charles Link's leadership, ChainLink Pharma is focused on developing novel immunotherapy agents for cancer. Additional roles include Board Member at Viewpoint Molecular Targeting, Inc. and member of the Board of Directors at QSAM Biosciences, Inc. Charles Link previously founded and led BioProtection Systems Corporation and served as Founder, Chairman, and CEO of NewLink Genetics for two decades. Charles Link's educational background includes degrees from Stanford University School of Medicine, the National Cancer Institute, Stanford University, and the United States Air Force Academy.